Globe Life offers whole and term life insurance products, Medicare supplements, and limited-benefit supplemental health coverage, distributed through direct-to-consumer channels, exclusive agencies, and independent agents. The company focuses on affordable insurance solutions for underserved middle-income markets, positioning itself as a stable provider with consistent dividend payments.
Cyborg Score Rationale
Globe Life reported strong Q4 earnings with net income of $266 million and raised 2026 guidance for net operating income to $14.95-$15.65 per share. Analyst consensus is 'Buy' with a 12-month price target of $161.89, representing 12.70% upside, reflecting confidence in growth trajectory.
Top Insights
Q4 2025 earnings beat with net income of $266 million and 2026 EPS guidance of $14.95-$15.65
For 2026, analysts expect adjusted EPS growth of 4.1% year-over-year to $15.12
Consistent dividend payer with mixed earnings surprise history but analyst consensus supporting buy ratings